Congenital Zika Syndrome: Symptoms, Causes & Treatment
the Dawn of Universal RSV Vaccines: A Landmark Achievement in Respiratory Disease Prevention
Table of Contents
For decades, respiratory syncytial virus (RSV) has been a important, yet largely unpreventable, cause of illness and hospitalization, particularly among infants and older adults. As of May 3, 2023, that landscape has dramatically shifted. The Food and Drug Governance (FDA) approved the first RSV vaccines for adults aged 60 years and older,and for use in pregnant people to protect their infants. Recent data, published in the New England Journal of Medicine (Volume 394, Issue 1, January 1, 2026), confirms the sustained efficacy and safety of these groundbreaking vaccines, marking a pivotal moment in public health.
Understanding RSV: The Virus and Its Impact
RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However,it can lead to severe complications,including bronchiolitis (inflammation of the small airways in the lungs) and pneumonia,especially in infants,young children,and older adults. Before the advent of these vaccines, RSV was responsible for an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually in the United States among older adults. Infants faced similar risks,with RSV being the leading cause of hospitalization in babies under one year old.
The virus spreads through respiratory droplets produced when an infected person coughs or sneezes. Symptoms typically appear 4-6 days after infection and include a runny nose, decreased appetite, cough, sneezing, fever, and wheezing. While most people recover within a week or two, severe cases can require hospitalization and supportive care.
The New Vaccines: how they Work
Two primary types of RSV vaccines have been approved:
- RSVPreF3 OA (abrysvo, Pfizer): This vaccine utilizes a prefusion F protein, a key component of the RSV virus, to stimulate an immune response. the prefusion F protein is more stable than other forms of the protein, leading to a stronger and more durable antibody response. Clinical trials demonstrated approximately 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) in adults 60 years and older.
- RSV-F213 (Arexvy, GSK): Similar to Abrysvo, Arexvy also employs a prefusion F protein. Trials showed approximately 82.6% efficacy in preventing RSV-associated LRTD in the same age group.
For pregnant people, the vaccine works by transferring protective antibodies to the developing fetus, providing passive immunity to the infant during the first few months of life. This is particularly crucial as infants are most vulnerable to severe RSV illness.
Key Findings from the New England Journal of Medicine (January 2026)
The January 2026 issue of the New England Journal of Medicine presented long-term follow-up data from the pivotal clinical trials. These findings reinforced the initial efficacy results and provided valuable insights into the vaccines’ safety profile over an extended period. specifically, the data indicated: